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Mini Abstract 
To determine how long vitamin D lasts after supplementation ceases, the marker of status was 
measured 2 and 3 years after a 1 year trial. Compared to placebo, the proportion of vitamin D-
deficient women was still lower, if they had taken daily vitamin D3, after 2 years, indicating its 
longevity. 
Abstract 
Purpose 
To determine longevity of vitamin D status following cessation of vitamin D3 supplementation, 2 and 
3 years after a 1-year randomised, double-blind placebo controlled trial; and to investigate possible 
predictive factors. 
Method 
Caucasian non-smoking postmenopausal women randomised to ViCtORY (2009-2010), who had not 
taken vitamin D supplements since the trial ended, were invited to attend follow up visits. Total 25-
hydroxyvitamin D (25OHD) and 24,25-dihydroxyvitamin D (24,25OH2D) were measured by dual 
tandem mass spectrometry of serum samples following removal of protein and de-lipidation; the 
original RCT samples were re-analysed simultaneously. Vitamin D binding protein (VDBP) was 
measured by monoclonal immunoassay.  
Results 
In March 2012 and March 2013, 159 women (mean (SD) age 67.6 (2.1) years) re-attended, equally 
distributed between the original treatment groups:  daily vitamin D3 400IU; 1000IU; and placebo. 
One month after the RCT ended (March 2010) the proportion of women in placebo, 400IU, and 
1000IU vitamin D3 groups, respectively, with 25OHD<25 nmol/ L was 15%,0%, 0% (Chi-square 
p<0.001, n=46,44,54). After 2 years (March 2012) it was 22%, 4%, 4% (p=0.002, n=50,48,57); after 3 
years 23%, 13%, 15% (p=0.429,n=48,45,52). The respective proportions of women with 24,25OH2D < 
2.2 nmol/L were 50%, 2%, 2% (1 month, p>0.001, n=46,44,54); 42%, 33%, 12% (2y, 
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p=0.002,n=50,48,57) and 45%, 27%, 29% (3y, p=0.138, n=47,45,51,). VDBP was a predictor of 
circulating 25OHD longevity (beta for VDBP in μg/ml:0.736; 95% CI 0.216-1.255,p=0.006) but not 
24,25OH2D. 
Conclusion 
400 IU (or 1000 IU) daily vitamin D3 showed benefits over placebo 2 years after supplementation 
ceased, in keeping 25OHD >25 nmol/L.  
KEY WORDS: Daily vitamin D, 25-hydroxyvitamin D, 24,25-dihydroxy vitamin D, RCT, longevity, 
postmenopausal women  
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INTRODUCTION 
Vitamin D continues to be the subject of controversy with regard to health outcomes1,2, and the 
exponential increase in often inappropriate testing of 25-hydroxyvitamin D [25OHD], for assessing 
vitamin D status, continues to be a burden on health resources 3 . Whereas population observational 
studies suggest a beneficial association between vitamin D status and many health outcomes, more 
recent intervention studies have been less convincing 4.  A number of other structured literature 
reviews and meta-analyses have been performed with mixed conclusions 1,5-7. Government 
evaluations of the evidence have concluded that only in the case of musculoskeletal health is the 
role of vitamin D well-founded 8-10. 
Lack of sunlight for cutaneous synthesis of vitamin D; and the limited amount of vitamin D present 
naturally in the diet; lie behind concerns about vitamin D deficiency in Northern Europe and the US. 
The past assumption that vitamin D made in the summer lasted over the winter months 11 has 
largely been dismissed on the basis of the half-life of circulating 25OHD being only a few weeks 12.  
Yet the half-life estimates of 25OHD are based on extrapolation of data from short-term studies 13,14 
and there are no measured long-term data on the longevity of vitamin D following cessation of 
supplementation.  The Scientific Advisory Committee of Nutrition (SACN) recommended a reference 
nutrient intake (RNI) of 400 IU daily vitamin D for all adults in the UK 9, compared to 600IU being 
recommended in the US and Europe 8,10. 
‘Vitamin D’ intervention and dosing studies have consistently shown that the lower the starting 
25OHD the greater the increase 15,16; and progressively higher doses of vitamin D result in smaller 
incremental increases in 25OHD 17,18.  It is uncertain whether additional vitamin D is incompletely 
absorbed, or metabolised more quickly and excreted, suggesting that there is no benefit to taking 
higher doses; or whether it is stored (or converted to other metabolites that are either stored, or 
protected from degradation), allowing additional amounts to be used in the future. The role of 
vitamin D binding protein (VDBP) in binding 25OHD has been suggested as one way that 25OHD is 
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protected from degradation 19. Most research on VDBP has focussed on adjusting 25OHD for VDBP in 
the belief that it is free, not total, 25OHD that is associated with health outcomes 20. Criticisms have 
been raised regarding the limited data available for the equations used to estimate free 25OHD, and 
the monoclonal immunoassay used to measure VDBP 21.  
Although it is only 1,25 dihydroxyvitamin D that has biological activity (circulating at concentrations 
of pmol/L and under homeostatic control), and 25OHD that is the accepted marker of status; there is 
interest in other vitamin D metabolites, particularly 24,25 dihydroxyvitamin D (24,25OH2D) with 
research focusing mainly on its interference in the measurement of 25OHD 22 . This metabolite, 
which circulates at 1/13 of the concentration of 25OHD, is the first step on the degradation pathway 
23 but what role, if any, it might play in health is unknown.  There are few data on the status of 
different vitamin D metabolites especially from intervention studies 24,25. 
The VICtORy (VItamin D and CardiOvascular Risk) RCT  in 2009-10 had all participants starting at the 
beginning of the year, when 25OHD is at its lowest in the UK, allowing direct bimonthly comparison 
between the treatment and placebo groups throughout the year. It found that there was no effect of 
daily vitamin D3 treatment (400 IU or 1000 IU) on conventional markers of cardiovascular risk at any 
point 26.   Bone mineral density (BMD) scans taken at the start and end of the study, showed that hip 
bone loss was reduced in the group taking 1000IU daily vitamin D, but not in the 400IU group, 
although the difference in 25OHD increase between the two groups was small 18. The aim of this 
RECALL study was to determine the longevity of vitamin D supplementation, by testing for 
differences in the proportion of women with 25OHD < 25 nmol/L, and any differences in 24,25 
dihydroxyvitamin D (24,25OH2D), two and three years after the VICtORY study intervention phase 
had ended; and to determine possible predictive factors  associated with better vitamin D status.  
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METHODS 
Population and participant involvement 
The women in this study were healthy non-smoking postmenopausal women mean age (SD) 64.7 
(2.1) y who had taken part in a placebo controlled randomized controlled trial of vitamin D3 
between January 2009 and February 2010 26 and attended a ‘decay visit’ in March 2010, 1 month 
after study completion.  The results of the VICtORy RCT, which showed no difference in markers of 
cardiovascular risk, inflammation, or glucose tolerance after 1 year between the 2 treatment groups 
(400 IU and 1000 IU daily vitamin D3) and placebo; and an identical seasonal decrease on blood 
pressure for the 3 groups, were presented to the volunteers (n=287 of 305 who took part) at one of 
three presentations.  The BMD data were not available for dissemination. The formal presentation 
was followed by an informal lunch with the researchers, and the opportunity to ask questions. It 
meant that when the women were recalled in 2012 most had not taken vitamin D supplements since 
the study ended. We anticipated that one half the women originally randomised would be willing 
and eligible to return (n 152). Some women were taking cod liver oil capsules containing < 5 μg (200 
IU) vitamin D3 a day and this was adjusted for in the statistical analysis. A group of 3 VICtORy RCT 
participants advised on the RECALL study design prior to its implementation, in particular their 
opinions on wearing UV exposure badges. Ethical approval for the RECALL study was provided by 
North of Scotland Research Ethics Committee (12/NS/0013), and all women gave informed consent.  
RECALL visits 
Women were invited to attend additional visits in March 2012 and March 2013 (two years and three 
years after the original trial had ended). Those who agreed to take part (n=159, mean [SD] age 67.6 
[2.3] y), confirmed that they had not taken vitamin D supplements since the study ended and were 
not intending to take extended holidays abroad. A flow diagram showing the numbers of women at 
the start and end of the original RCT, and the numbers in the RECALL study is shown in Figure 1. At 
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both RECALL visits the women were weighed on calibrated weighing scales (Tanita Europe BV, 
Amsterdam, The Netherlands), their height measured by stadiometer (Holtain Ltd Crymych UK), and 
blood pressure measured using a Omron 705CP sphygmomanometer (Omron, Herts UK). Lean and 
fat body mass was obtained from whole body scans at the final RCT visit (V6) using dual energy X-ray 
absorptiometry (DXA; Lunar iDXA, GE Medical Systems Inc, Madison, WI) and a blood sample was 
taken for measurement of 25OHD. As a result of changes in analytical procedure to remove 
artefacts, the samples were analysed together with re-analysis of the original study samples. The 
researchers seeing the volunteers and analysing the data; and the laboratory carrying out the 
analysis remained blind to the intervention groups. 
 
Diet had been assessed by food frequency questionnaire at 2-monthly intervals during the VICtORy 
trial 26. The women again completed the FFQ at the first RECALL visit (March 2012). In March 2013, 
those whose diet had changed in the previous year completed an additional FFQ. Any vitamin D 
obtained from cod liver oil was added to the dietary vitamin D. 
At each visit, skin colour was measured at the forearm, and left and right cheekbones using a hand-
held chromameter (CM-2600d spectrophotometer; Konica Minolta Photo Imaging (UK) Ltd., 
Feltham, UK). The measurements obtained for L*(dark-light) and b*(blue yellow) axes of colour were 
used to estimate the individual topology angle (ITA, an indication of melanin pigment in the skin 
where the higher the ITA, the lighter the skin colour) according to the following equation ITA = 
[arctangent(L* - 50)/b*] x 180/π 27. The women also reported their skin type 28. 
 
In between the two RECALL visits the women were sent badges every month, to wear for 1 week to 
assess UV radiation exposure, which they returned by post. The UVB badges were disposable, made 
of polysulphone film; one was worn for 3 days and replaced by a second one on day 4 for the rest of 
the week. The absorbance at 330nm of the polysulphone badge was measured using a 
spectrophotometer (Perkin-Elmer UV/VIS Lambda 2 spectrophotometer) before and after wearing 
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(Δ330), and converted to standard erythemal dose (SED) using the equation: SED =10.7(ΔA330) + 
14.3 (ΔA330)2 - 26.4 (ΔA330)3 + 89.1(ΔA330)4 29. One SED is equivalent to 100 J/m2 UV radiation 
exposure. The SED estimates from each badge were summed to obtain the weekly total. Typically, a 
person would receive 1 SED/ day UV exposure during the summer in Aberdeen 30. A subset of 
women also wore UVA badges (purchased from Scienterra Ltd, Oamaru, NZ), which were electronic 
devices that continuously recorded data. Algorithms (written by Maciej Gryka) were used to extract 
the data collected during the week they were worn by the volunteers. The badges had been 
calibrated with the assistance of Dr Martin Allen (Health Protection Agency, Cambridge) enabling the 
readings to be converted to SED equivalents.  At the final visit women provided details about 
holidays to sunny destinations during the previous year, for testing in the statistical models. Women 
were also asked if they had been away for >1 month between the end of VICtORY RCT and the start 
of the RECALL study, and a sensitivity analysis was done excluding these women. 
 
Laboratory Measurements 
Circulating vitamin D metabolites and parathyroid hormone (PTH) were measured at the University 
of East Anglia. 25OHD3, 25OHD2, 24,25OH2D3 and 24,25OH2D2 were measured simultaneously by a 
published liquid chromatograph tandem mass spectrometry (LC-MS/MS) method 25. In brief, 100μL 
of sample spiked with [2H6]-24,25-OH2D3 and [2H6]-25OHD3 as internal standards was extracted 
using supported liquid extraction (SLE) for removal of phospholipids followed by derivatisation with 
4-phenyl-1,2,4-triazoline-3,5-dione (PTAD) to enhance ionisation efficiency. Measurements of 
25OHD3 were calibrated using commercial 25OHD3 standard materials (Chromsystems, München, 
Germany) that were traceable to reference source NIST SRM972a. The inter-assay CV for 25OHD3 
and 25OHD2 were ≤9% across the analytical range between 0-200 nmol/L, with lower limit of 
quantification (LLoQ) at 0.1 nmol/L. Mean assay recovery was 96 r2%. Vitamin D external quality 
control (DEQAS) returns showed the accuracy bias of 25OHD3 measurements against NIST reference 
method was <8%. Measurements of 24,25OHD3 and 24,25OHD2 were calibrated using commercially 
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certified standard materials spiked into human based vitamin D-depleted serum. The inter-assay CVs 
were <10% across the analytical range between 0-25 nmol/L, with LLoQ at 0.1 nmol/L. Mean assay 
recovery was 97 r4%. DEQAS returns on 24,25OH2D3 showed a 2% bias against all laboratory 
trimmed mean. PTH was measured in plasma samples using an electrochemiluminescent 
immunoassay (ECLIA) on a Modular Analytics E170 analyzer (Roche Diagnostics, Burgess Hill, UK). 
Inter/intra-assay coefficient of variation was <4% from 1 to 30 pmol/L. The assay sensitivity 
(replicates of the zero standard) was 0.8 pmol/L.  
 
Vitamin D Binding Protein (VDBP) 
VDBP was measured in Aberdeen using a monoclonal enzyme-linked immunosorbent assay (Human 
vitamin D BP QuantikineELISA Kit; R&D Systems, Oxford, UK) according to the manufacturer’s 
instructions. The inter-/intra-assay CV was <7.4 and <6.2%, respectively, across the working range. 
 
Statistical analysis 
All analyses were done using SPSS version 24 with pre-planned analysis. Dependent variables were 
transformed using the natural logarithm (Ln) if required. Independent t-tests were used to check the 
characteristics between RECALL participants and those who did not take part. Chi square tests were 
used to test differences in the number of women with 25OHD < 25 nmol/L and 24,25OH2D < 2.2 
nmol/L (the threshold equivalent to 25 nmol/L 25OHD) between treatment groups.  Linear 
regression was used to relate the 25OHD measurements obtained by the two different tandem mass 
spectrometry procedures (original and modified de-lipidation method).  Repeated measures ANOVA 
was performed for testing differences in vitamin D metabolites and PTH according to study visit and 
treatment group; and to detect any differences in monthly sunlight exposure during 2012-3, 
between treatment groups. Mixed model analysis was undertaken to determine the predictors of 
25OHD and 24,25OH2D at the RECALL visits (2-visit model). A 4-visit model compared the last four 
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vitamin D metabolite measurements (at the end of the VICtORy intervention, 1 month later, 2y later, 
and 3y later). Both models tested factors that might influence the change in vitamin D metabolites 
(treatment group, use of cod liver oil supplements, lean body mass, fat mass, passive smoking, 
dietary vitamin D and other nutrients [vitamin A, preformed retinol, calcium, protein, fat, 
carbohydrate and energy], sunlight behaviour, holidays abroad, skin type, VDBP). There were few 
data points missing for the main mixed model and the missing data were assumed to be missing 
completely at random. 
 
RESULTS 
Of the 265 women who completed VICtORY, 236 responded (89%): 43 (16%) taking > 400 IU daily 
vitamin D (some prescribed supplements as an adjunct to osteoporosis treatment) were excluded; 
25 were unable (other commitments, travel, or unknown); and 9 responded positively after the 
deadline (Figure 1). A total of 159 women attended the RECALL visits (n=52, n=49, n=58, respectively 
for placebo, 400 IU, and 1000 IU- vitamin D treatment groups). There were no differences in 
characteristics according to their original treatment allocation except for VDBP, where mean [SD] 
was significantly higher for the 400IU group (296 [44]μg/ml) compared to 1000 IU (244 [89]μg/ml) 
(post hoc ANOVA p=0.02) (Table 1). There were no differences between the women attending and 
not attending the RECALL study, in terms of age, height, and starting vitamin D status, but those who 
took part were slightly heavier (Supplementary Table 1).  
Comparison of 25OHD obtained by the original tandem mass spectrometry method with a modified 
method that included a de-lipidation procedure 
The results of 25OHD using the original method have been reported previously26. The de-lipidation 
step introduced for the 25OHD measurements, reported here, resulted in greater recovery of 
25OHD.  An equation relating the two was obtained by linear regression analysis:   
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Ln(25OHD with delipidation)= 0.859 x Ln(25OHD without delipidation) + 0.773 (R=0.904) 
The modified method gave higher mean (SD) 25OHD concentrations (n=2032 measurements for 
comparison: Total 25OHD: 68.6 (26.9) vs 55.4 (23.0) nmol/L; 25OHD2: 1.7 (1.1) vs 1.0 (1.4) nmol/L; 
25OHD3: 66.9 (27.2) vs 54.4 (23.1) nmol/L), and fewer women with 25OHD < 25 nmol/L . The 
percentages of women who took part in the RECALL study with 25OHD< 25 nmol/L at the start of the 
RCT, using the original method was 34.6, 28.6 and 32.8 for placebo, 400 IU and 1000 IU respectively 
(Chi-square p=0.802); whereas using the modified method it was 13.0,8.2 and 12.7, respectively 
(Chi-square p=0.694).  
Numbers of women below thresholds for 25OHD and 24,25OH2D 
The percentage of women with 25OHD < 25 nmol/L, and 24,25OH2D < 2.2 nmol/L at each visit are 
shown in Figure 2.  For the placebo group, the percentage with 25OHD < 25 nmol/L decreased 
gradually at each visit until July-August (the only visit where no-one had 25OHD < 25 nmol/L ) and 
then gradually increased until the end of the study. For the treatment groups there was a rapid 
increase in 25OHD so that no participant had 25OHD< 25 nmol/L after 2 months treatment, and 
although mean 25OHD had decreased 1 month after the intervention ceased, no-one had fallen 
below the 25 nmol/L threshold (Figure 2).  One month after the RCT ended (March 2010) the 
respective number of women in placebo, 400IU, and 1000IU vitamin D3 groups, with 25OHD<25 
nmol/ L was 15%,0%, 0% (p<0.001, n=46,44,54). After 2 years (March 2012) it was 22%, 4%, 4% 
(p=0.002, n=50,48,57); after 3 years 23%, 14%, 17% (p=0.429, n=48,45,52).  Using the 24,25OH2D 
marker, there was a similar pattern for the 2.2 nmol/L cut off. The respective number of women 
with 24,25OH2D < 2.2 nmol/L was 50%, 2%, 2% (1 month, p>0.001, n=46,44,54); 42%, 33%, 12% (2y, 
p=0.002, n=50,48,57) and 45%, 27%, 29% (3y, p=0.138, n=47,55,51). 
The mean circulating concentrations of 25OHD and 24,25OHD (Figure 3) had similar trajectories: the 
placebo showing a marked season pattern with much lower circulating concentrations than either 
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treatment group, even in summer. There was little change in 1,25OH2D and PTH (the latter two 
analytes were collected at selected visits only) (Figure 3).  
Dietary vitamin D and sunlight 
Mean (SD) daily dietary intake of vitamin D was 5.1 (3.4) μg in both 2012 and 2013 (Table 1). Cod 
liver oil was taken by 37 participants, averaging intake 1.2 (2.4) μg/d in these individuals and 
increasing overall mean (SD) dietary vitamin D intake to 6.4 (4.1) μg/d. 
The sunlight exposure of the subset of women who wore badges (supplementary figure 1) showed 
similar monthly patterns for UVB and UVA, and no differences between treatment groups (repeated 
measures ANOVA). The two variables were highly correlated (Spearman coefficient 0.7, P<0.001).  
Women who had been on holiday abroad for longer than one month since the study finished (n 22) 
had higher circulating 25OHD compared to the rest of the women (55.5[24.7] n=21 versus 46.2 
[18.9] n=126), although not significant.  
Mixed model analysis of 25OHD and 24,25OH2D measurements following the end of the VICtORy RCT 
The mixed model which included the last four 25OHD measurements (at the end of the intervention, 
+1 m, +2y, and +3y) showed the time variable and the original study group to be significant 
predictors of 25OHD. Dietary energy intake and VDBP were additional significant predictors, with 
VDBP positively associated; and dietary energy negatively associated with 25OHD. Dietary vitamin D 
and vitamin A were not associated with 25OHD. Although dietary fat, protein, carbohydrate and 
dietary calcium intake appeared to be significant predictors of 25OHD, when tested independently, 
the relationship disappeared when dietary energy was included, due to the correlation between 
these macronutrients and dietary energy intake. Weight, height, age, sunlight behaviour, body fat 
mass, and lean mass (collected at the end of the VICtORy intervention period18) were not significant 
predictors of 25OHD (Table 2, Model 1).  
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The second model for the last two 25OHD measurements (2012 and 2013) tested skin colour, and 
participants’ sunlight behaviour, including the total number of days spent abroad on holiday 
between the two visits. Again visit, treatment group and VDBP were significant predictors of 25OHD, 
but not dietary energy intake. In this model the use of cod liver oil supplements, darker arm skin 
colour, and number of days spent abroad indicated higher vitamin D status. (Table 2, Model 2a). 
Finally a subset analysis in which there was more detailed information on sunlight exposure 
obtained from wearing UV detection badges, showed that overall UVB (but not UVA) exposure was a 
weak negative predictor of 25OHD (Table 2, Model 2b).  
VDBP was not a predictor of 24,25(OH)2D (Table 2). Only ‘holidays abroad’ remained a positive 
predictor in the final 4-visit model . For the 2-visit model, as for 25OHD, supplement use was a 
positive predictor and there was a weak negative association with UVB and not UVA exposure.  
For both vitamin D metabolites, there were significant associations with 1,25OHD (positive) and PTH 
(negative) when these were added; but only with 1,25OH2D in the subset model 2b. Sensitivity 
analysis excluding women abroad for longer than 1 month since the RCT finished showed no overall 
differences except for PTH no longer being a significant predictor of 25OHD in the 4-visit model. 
The characteristics of women below and above the thresholds at the final RECALL visit (when there 
was no longer a difference between treatment groups) showed differences in 1,25(OH)2D  and 
25OHD before the RCT started, for 25OHD; and also supplement use for 24,25OH2D (supplementary 
Table 2).  
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DISCUSSION 
We believe that this is the only long-term study to examine vitamin D status after completion of a 
placebo-controlled RCT of low dose, daily vitamin D3.  Our data, showing that vitamin D 
supplementation is still evident 2-years but not 3-years after cessation, are consistent with a 1-year 
single-arm study in 45 nursing home residents providing 5000 IU vitamin D daily from vitamin D-
fortified bread, which showed that 25OHD measured in 23 residents was higher compared to 
baseline 1 year after the study (64.9 ± 24.8 nmol/L) but not 3 years (28.0 ± 15.0 nmol/L) 31. They 
support our longitudinal data over 3 years, indicating that for the majority, circulating 25OHD does 
not decrease below a set minimum30.  
We hypothesise that during winter at high latitude, circulating 25OHD is prevented from decreasing 
below a set point for a period, either being topped up from stores when required, or being 
protected from degradation to some extent. It is only when the store or protected 25OHD has been 
exhausted that people become at risk of vitamin D deficiency: when usage begins to outstrip 
provision, and the conversion to 1,25OH2D becomes less efficient.  
Although vitamin D stored in the body was considered important in maintaining 25OHD over 
winter32, other evidence from pig models 33 suggest that the size of vitamin D stores is limited 34.   
There is some uncertainty regarding the exact contribution that sunlight and diet provide to the 
overall vitamin D economy 35,36, although direct observations show that 80%-90% 25OHD comes 
from summer sunlight in the UK, with 25OHD  increasing rapidly  in summer, against a background 
where dietary vitamin D remains constant 37.  Depending on time of day, latitude and skin 
pigmentation, 5 to 15 minutes exposure to summer UVB is required to make sufficient vitamin D 38 
but it is unclear how much is stored long-term, compared to vitamin D from the diet.  It is possible 
there may be sunlight/ oral vitamin D interactions, as VICtORy treatment doses were not additive, 
contributing less to total 25OHD in the summer, compared to autumn 18.   
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VDBP was a factor affecting the half-lives of 25OHD2 and 25OHD3 19.  Our data suggest that VDBP 
may play a minor role in extending the half-life of circulating 25OHD in this population, but it is likely 
there must be other mechanisms which preserve 25OHD.  VDBP was measured at one visit only 
(March 2010, the same month as the two RECALL visits). The downside of the monoclonal 
immunoassay in failing to detect other genotypes of VDBP 21 may be less relevant within a single 
Caucasian population. It is possible that VDBP concentrations could change according to season, and 
affect how much 25OHD is metabolised, but we cannot test that hypothesis in this study.  Jamil et al. 
found that VDBP was lower in spring compared to autumn in South East Asians living in Aberdeen, 
UK 39.   
Other predictors were similar to those tested previously 30. We did not find that individual dietary 
vitamin D intake predicted vitamin D status, although use of cod liver oil capsules (providing an 
additional 200 IU vitamin D) was important. The finding that darker skin colour, and holidays abroad 
between the recall visits (2012-2013) were associated with greater 25OHD is in keeping with more 
sunlight exposure leading to greater cutaneous synthesis of vitamin D. The weak negative 
association between UVB exposure obtained from the badges and 25OHD was unexpected, but may 
indicate some interaction between diet and sunlight as suggested earlier; or reflect that once 
sufficient vitamin D is synthesised, spending longer outside will not result in more vitamin D 40. The 
benefit of holidays abroad and cod liver oil supplements has been noted in our cross-sectional and 
longitudinal studies 41 42. Three years after the RCT, 17% of participants had 25OHD < 25 nmol/L, 
with the main difference between those below and above the cut-off being the 25OHD 
measurement before the intervention started. Whether women revert to original behaviour after 
taking supplements (eg sun avoidance, diet low in vitamin D) or there is genetic predisposition to 
lower 25OHD43  is unknown. Whatever the reason, our data show that small amounts of daily 
vitamin D are effective in preventing deficiency in this group. Tracking of 25OHD over 10 years has 
been noted in longitudinal studies 30,44. 
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Comparing the metabolite 24,25(OH)2D with the established marker of status, 25OHD, showed 
similar trajectories in response to supplementation, with perhaps a greater difference in 
24,25(OH)2D response between 400IU and 1000IU vitamin D3 than for 25OHD, indicating a lower 
25OHD:24,25OH2D ratio. This is consistent with observations that 25OHD:24,25OH2D ratios are 
higher when 25OHD is < 50nmol/L 25.  The longer maintained increase in 24,25(OH)2D with 1000IU 
vitamin D supplementation would indicate a different rate of metabolism or production from stores 
for 24,25(OH)D compared to 25OHD. Unlike 25OHD, VDBP had no association with 24,25OHD 
longevity. Although we tested 1,25(OH)2D and PTH as additional variables in the models, the 
dependency is likely to be reversed, with 25OHD and 2425OH2D affecting 1,25(OH)2D positively and 
PTH negatively.  
The accepted 25OHD half-life of a few weeks has been based on extrapolation of short-term data 13. 
If there are feed-back mechanisms that prevent the continued rate of decay beyond a set minimum, 
these would be missed.  If we had extrapolated 25OHD from our 1-month decay visit, which showed 
a rapid initial decrease after treatment ceased, we would have concluded that any difference in 
25OHD would have disappeared within months. Our measured data at two years show that was not 
the case. Our findings indicate that it will be those who year-on-year do not get enough sunlight and 
who do not reach the RNI who are going to suffer frank vitamin D deficiency, leading to symptoms; 
as any protective mechanisms cannot keep going indefinitely.  
SACN’s risk assessment concluded that, as it could not recommend how much summer sunlight 
exposure was required to maintain adequate vitamin D status in the winter, the RNI of 400 IU should 
apply to all adults 9. It was not within SACN’s remit to consider approaches to achieve this. It remains 
a concern that those who are deemed most at risk of vitamin D deficiency do not get enough vitamin 
D. Despite the RNI for vulnerable groups existing since 1991, with recommendation of vitamin D 
supplements, it is clear that this message has not been reaching many in the ‘at risk’ groups. It is 
likely that any voluntary fortification of foods by manufacturers would necessitate surcharges that 
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might render such items unaffordable to those most in need; and that mandatory fortification of 
foods most likely to be consumed by different populations should be considered.  Our data imply 
that the amounts needed are small enough not to place any risk to those currently getting sufficient 
vitamin D through a combination of summer sunlight and diet.  
We did not find any influence of other nutrients, for example calcium, considered to be ‘vitamin D 
sparing’ 45, or vitamin A; but the FFQ may be insufficiently sensitive to detect small differences. The 
interaction of other nutrients with vitamin D may be more important in predicting health outcomes. 
Other limitations of the RECALL study are that the women who took part could be different from 
those randomised to the RCT, but we found no significant difference in 25OHD, nor the percentage 
below the deficiency cut-off. Although it is possible that some women, despite their stating 
otherwise, had taken vitamin D supplements since the study finished; it is unlikely that this applies 
to everyone, as they had been presented with results showing that there was no benefit of vitamin D 
supplementation on cardiovascular risk markers. If those on placebo had started taking vitamin D, 
this would have narrowed the margins between the treatment groups.  In either scenario, the 
women would have had to purchase vitamin D supplements themselves to continue. The 
generalisability of the study is restricted to outwardly healthy Caucasians in the UK, and highlights 
the need for concentrating resources on ethnicities at increased risk of vitamin D deficiency. 
The strengths are that the study was carried out at 57°N, with no UVB radiation between April and 
October, and averaging less summer sunlight exposure than the rest of the UK37. The daily doses of 
400 IU and 1000 IU vitamin D3 are relevant to population recommendations, the former being the 
current UK RNI (400IU), and well below recommended safe upper limits. All volunteers started the 
original study in January-March, and the decay and RECALL visits were in the same month (March). 
In addition, the improved methodology for measurement of vitamin D metabolites, with all samples 
being analysed together, ensures robustness of the measurements. 
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In conclusion, 400 IU (or 1000 IU) vitamin D3 taken daily for 1 year still showed benefits over placebo 
2 years after the supplementation stopped, in terms of reducing the number of people with 25OHD 
< 25 nmol/L.  The benefit was no longer significant after 3 years.  The findings support the RNI of 400 
IU daily vitamin D in adults in order to protect the UK population from risk of vitamin D deficiency; 
and appropriate risk management strategies should be implemented.  It is recommended that 
25OHD measurement by tandem mass spectrometry adopts a de-lipidation procedure to allow 
better comparisons between studies and when using stored samples.  
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Table 1 Characteristics of RECALL participants (measured in 2012 unless otherwise indicated) 
according to treatment allocation for the original VICtORy RCT 
 
Mean (SD) Placebo 400 IU vitamin D3 1000 IU vitamin D3 P 
n 52 49 58   
Age (y) 67.5 (2.1) 67.4 (1.8) 68.0 (2.2) 0.222 
Weight (kg) 69.6 (11.3) 70.0 (12.7) 71.1 (11.1) 0.771 
Lean mass (kg) * 38.6 (3.7) 38.3 (4.6) 38.5 (4.4) 0.804 
Fat mass (kg) * 29.0 (8.0) 29.1 (8.8) 30.0 (8.4) 0.806 
Systolic Blood Pressure 
(mm Hg) 
128 (16) 129 (16)  127 (15) 0.842 
Diastolic Blood Pressure 
(mm Hg) 
75 (8)  75 (9)  76 (7) 0.926 
n 50 47 54  
vitamin D (diet only)(μg) 5.5 (3.6) 5.2 (2.9) 4.8 (3.5) 0.517 
vitamin D (diet + 
supplements) (μg) 
6.3 (4.4) 6.1 (3.4) 6.7 (4.4) 0.786 
Dietary calcium (mg) 1327 (441) 1242 (741) 1269 (630) 0.784 
VDBP (μg/L) 263 (90) 296 (97) 244 (89) 0.021 
PTH (pmol/L) 5.6 (1.7) 5.2 (2.1) 5.0 (1.3) 0.223 
n 52 49 58  
25OHD (nmol/L) at RCT 
start (in 2009) 
36.1 (18.7) 33.3 (12.6)  33.2 (15.5) 0.559 
25OHD (nmol/L) at end of 32.6 (15.6) 66.6 (20.6) 74.6 (20.1) <0.001 
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RCT (in 2010) 
1,25OH2D (pmol/L) at 
start of RCT ** 
135 (42) 138 (38)  132 (42) 0.700 
1,25OH2D (pmol/L) at end 
of RCT ** 
127 (42) 145 (46) 134 (42) 0.098 
n 46 49 55  
25OHD (nmol/L) at RCT 
start (after de-lipidation) 
43.6 (21.1) 46.2 (19.2)  43.7 (21.7) 0.789 
25OHD (nmol/L) at end of 
RCT (after de-lipididation) 
43.6 (18.9) 84.8 (17.2) 91.1 (24.3) <0.001 
24,25OHD (nmol/L) at RCT 
start (after de-lipidation) 
2.9 (1.9) 3.1 (1.5) 3.0 (2.0) 0.893 
24,25OHD at end of RCT 
(after de-lipidation) 
2.8 (1.5) 6.4 (1.6) 7.7 (2.7) <0.001 
Categories     
Time abroad > 1 month 
since RCT 
14.3 20.8 9.3 0.254 
Passive smoker (%) 7.8 4.2 12.1 0.336 
* measured at V6 (end of RCT) 
**1,25OH2D measured by immunoassay   
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Supplementary Table 1. Differences in characteristics, measured at randomization for the VICtORY 
RCT (in 2009), between RECALL participants and those who did return for the RECALL visits (in 2012) 
* 25OHD measured by the tandem mass spectrometry but no de-lipidation of samples 
**1,25OH2D measured by immunoassay  
SED standard erythemal dose (100 J m-2) estimated from polysulphone badges  
Mean (SD) RECALL VICtORy non-returners p 
n 159 146  
Age (y) 64.7 (2.1) 64.5 (2.3) 0.499 
Height (cm) 161 (6) 161 (6) 0.425 
Weight (kg) 70.6 (11.1) 67.4 (12.8) 0.018 
Grip strength 22.3 (4.8)  22.5 (4.9) 0.784 
25OHD (nmol/L) * 34.3 (15.8) 33.4 (13.6) 0.915 
1,25OH2D (pmol/L)** 139 (46) 137 (41) 0.714 
n 158 137  
Dietary vitamin D (μg/d) 5.0 (2.7) 5.7 (4.8) 0.119 
Dietary calcium (mg) 1272 (528) 1285 (482) 0.822 
n 153 140  
Sunlight exposure  
baseline (SED/ week) 
0.85 (0.92) 0.89 (1.18) 0.761 
n 151 114  
Sunlight exposure  july-
august (SED/ week) 
6.15 (5.02) 7.13 (10.03) 0.302 
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Table 2 Mixed model analysis to determine predictors of (A) 25OHD and (B) 24,25(OH)2D following cessation of supplements.  
 
 
(A) 25OHD (nmol/L)  (B) 24,25OH2D (nmol/L)  
Independent Variables Beta 95% CI P Beta  P 
Model 1 (4-visit) (n 158)       
Constant 3.919 3.673-4.164 <0.001 1.264 1.112 to 1.415 <0.001 
Visit       
Study end 0.493 0.349 to 0.636 <0.001 0.566 0.448 to 0.684 <0.001 
+1 month 0.376 0.238 to 0.513 <0.001 0.476 0.368 to 0.585 <0.001 
+2 year 0.123 0.036 to 0.210 0.006 0.132 0.046 to 0.217 0.003 
+3 year 0      
Treatment group       
placebo -0.745 -0.869 to -0.620 <0.001 -0.951 -1.090 to -0.811 <0.001 
400 IU -0.080 -0.208 to 0.048 0.216 -0.165 -0.306 to -0.024 0.022 
1000 IU 0      
VDBP (μg/L) 0.736 0.216 to 1.255 0.006    
Dietary energy intake 
(J/d) 
-0.030 -0.048 to -0.011 0.002    
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Holiday abroad yes no    0.170 0.067 to 0.274 0.001 
UVB year (SED) 0.479 x 10-3 0.044 x 10-3 to 0.914 x 10-3 0.031    
       
Additional variables       
1,25OH2D (pmol/L)  2.334 x 10-3 1.266 x 10-3to 3.403 x 10-3 <0.001 2.997 x 10-3 1.775 x10-3 to 4.218 x10-3 <0.001 
PTH (pmol/L) -0.039 -0.073 to -0.005 0.026 -0.068 -0.104 to -0.032 <0.001 
       
Model 2a (2-visit) (n 151)       
Constant 4.158 3.862 to 4.634 <0.001 1.338 1.126 to 1.545 <0.001 
Visit (+2 year vs +3 year) 0.082 0.020 to 0.144 0.010 0.133 0.048 to 0.218 0.002 
Treatment group       
placebo -0.203 -0.357 to -0.050 0.010 -0.273 -0.480 to -0.067 0.010 
400 IU -0.112 -0.273 to 0.049 0.172 -0.162 -0.372 to +0.049 0.132 
1000 IU 0      
Supplements  +0.167 -0.321 to -0.013 0.034 0.356 0.151 to 0.561  0.001 
VDBP ug/L 0.645 -0.002 to 1.292 0.051    
Holidays (days abroad) +0.0038 0.0005 to 0.0071 0.025 0.0053 0.0008 to 0.0097 0.020 
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Arm skin colour (ITA) -0.0087 -0.0166 to -0.0009 0.029    
Additional variables       
1,25OH2D (pmol/L)  3.179 x 10-3 * 1.740 x 10-3 to 4.618 x 10-3 <0.001 4.203 x 10-3 2.271x10-3 to 6.135 x10-3 <0.001 
PTH (pmol/L) -0.045 * -0.076 to -0.129 0.006 -0.058 -0.100 to -0.015 0.008 
*VDBP, Supplements and Skin colour no longer significant predictors      
Model 2b (2-visit, sub-set) (n 73)      
Constant 4.168 3.897 to 4.456 <0.001 1.713 1.296 to 2.130 <0.001 
Visit (+2 year vs +3 year) 0.133 0.053 to 0.213 0.001 0.176 0.060 to 0.292 0.003 
Treatment group       
placebo -0.176 -0.381 to 0.029 0.092 -0.319 -0.621 to -0.018 0.038 
400 IU -0.034 -0.247 to 0.179 0.751 -0.155 -0.468 to 0.157 0.326 
1000 IU 0      
Supplements 0.420 0.203 to 0.636 <0.001 0.560 0.243 to 0.877 0.001 
UVB-April-March -0.001 -0.002 to +0.000 0.077 * -0.0016 -0.0032 to 0.0001 0.061 * 
Additional variable       
1,25OH2D (pmol/L)  3.800 x10-3 1.952 x10-3 to 5.648 x10-3 <0.001 3.698 x10-3 0.946 x10-3 to 6.450 x10-3 0.009 
 * P=0.030 when additional variable added  * P=0.036 when additional variable added  
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Model 1. Repeated measures was based on final VICtORy visit, +1m, +2y, and +3y time-points and included the main outcome measures 25OHD and 
24,25OH2D (log transformed).  Repeated variables tested included weight, dietary vitamin D and other dietary nutrients, 1,25(OH)2D, and PTH. Fixed 
variables tested included: visit, original treatment group, supplement use (CLO), total days holiday, VDBP, SED from VICtORy, sunlight behaviour 
Model 2a. Repeated measures was based on +2y and +3y time points only, and included the main outcome measurement. Repeated variables tested 
included weight, dietary vitamin D and other dietary nutrients, skin colour, 1,25(OH)2D, and PTH. Fixed variables tested included original treatment group, 
age, total days holiday, sunlight behaviour, VDBP 
Model 2b. As for model 2a above but for the subset of women who undertook sunlight exposure measurements.  Exposure to UVA and UVB were tested 
separately
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Supplementary Table 2 Characteristics of between women below and above thresholds for (A) 25OHD (25 nmol/L) and (B) 24,25OH2D (2.2 nmol/L) at the 
final RECALL visit 
 (A) 25OHD:  25 nmol/L  (C) 24,25OHD: 2.2 nmol/L  
Mean (SD) Below threshold n=25 Above threshold n=120 P Below threshold n=48 Above threshold n=95 P 
Age (y) 65.0 (2.3) 64.5 (2.0) NS 64.8 (2.2) 64.5 (1.9) NS 
Weight (kg) 71.9 (18.4) 70.6 (10.7) NS 71.0  (12.8) 70.2 (10.5) NS 
VDBP (ug/ml) 250 (91) 269 (93) NS 265 (91) 266 (95) NS 
Energy intake (MJ/d) 9.18 (2.88) 8.97 (3.24) NS 9.44 (4.21) 8.81 (2.56) NS 
Dietary fat (g/d) 82.5 (34.4) 81.8 (32.3) NS 86.4 (40.5) 80.8 (29.8) NS 
Dietary protein (g/d) 92.3 (28.6) 92.1 (35.30 NS 95.0 (41.5) 90.9 (30.5) NS 
Dietary vitamin D 
(ug/d) 
5.5 (3.1) 5.1 (3.4) NS 5.57 (3.5) 5.0 (3.3) NS 
Dietary calcium 
(mg/d) 
1330 (608) 1247 (491) NS 1299 (665) 1243 (420) NS 
UVB June (SED) 17.4  17.3 NS 17.9 (14.8) 17.3 10.6) NS 
UVB July (SED) 23.0 20.4 NS  23.4 (19.5) 19.7 (14.5) NS 
UVB Aug (SED) 24.8 24.2 NS 24.2 (15.6) 24.2 (14.0) NS 
Holidays  win12-
spr13 
11 (17) 19 (21)  15 (19) 20 (22)  
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47
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25OHD start V0 33.9 (15.7) 45.5 (20.0) <0.01 35.4 (15.9) 47.9 (20.1) <0.01 
25OHD summer V3 72.2 (28.6) 82.1 (20.5) NS 75.5 (24.8) 82.8 (19.9) 0.07 
25OHD end V6 67.5 (38.1) 76.0 (27.1) NS 66.8 (33.5)  78.3 (25.4) 0.04 
Arm skin colour (ITA) 55.6  (6.1) 52.5 (5.4) 0.01 53.5 (5.8) 52.7 (5.4) NS 
1,25OH2D pmol/L  
V9 
77.3 (35.2) 96.2 (35.2) 0.02 82.3 (29.4) 99.1 (37.2) 0.08 
PTH pmol/L V9 5.5 (2.0) 5.3 (1.6) NS 5.7 (1.9) 5.2 (1.5) NS 
Categories        
% in placebo, 400 IU 
and 1000 IU 
44, 24, 32 31, 32, 37 NS 44, 25, 31 27, 35, 38 NS 
Supplement user % 12.0 25.0 NS 12.5 28.4 0.03 
Passive smoker 12.5 7.6 NS 6.4 9.5 NS 
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Figure 1 Participant flow diagram 
Figure 2 Deficiency thresholds (A)25OHD (B) 24,25OH2D 
 
Figure 3 Mean (A) 25OHD (new method) (B) 24,25OH2D (C) 1,25OH2D (D) PTH 
Supplementary Figure 1 Monthly UV exposure throughout 2012-2013 in a subset of VICtORY RECALL  
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Placebo  
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90 
11 discontinued  
7 excluded medication  
3 health issue 
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18 discontinued  
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5 health issue 
2 no reason  
400 I.U. vitamin D3  
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1000 I.U. vitamin D3  
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85 90 
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38 did not attend  
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4 unable 
5 gave no reason  
1 no contact address 
5 no response 
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36 did not attend 
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32 did not attend  
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3 discontinued 
1 changed mind 
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VICtORy RECALL STUDY 
265 invited 
 
FINAL RCT (V6) AND OPTIONAL 1 MONTH POST-RCT (V7) VISITS 
Figure 1 Click here to download Figure Figure 1-update.docx 
Figure 1.  
A 
 
 
B 
 
Figure 2 Click here to download Figure Figure 2 png.docx 
  
 
 
Figure 3 Click here to download Figure figure 3 portrait.docx 
Figure Legends footnotes 
Figure 2. Percentage of RECALL participants below selected deficiency cut-offs for vitamin D status 
A. Percentage of participants with 25OHD < 25 nmol/L for placebo, 400IU, and 1000IU daily 
vitamin D, respectively, was V0: 13, 8.2, 12.7; V1: 20.8, 0, 0; V2: 6.4, 0, 0; V3: 0, 0, 0; V4: 6.3, 
0, 0; V5: 18.2, 0, 0; V6: 14.6, 0, 0; V7: 15.2, 0, 0; V8: 22, 4.2, 0; V9: 22.9, 13.3, 15.4 
B. Percentage of participants with 24,25OHD < 2.2 nmol/L for placebo, 400IU and 1000IU daily 
vitamin D, respectively, was V0: 45.7, 30.6, 40.0; V1: 52.1, 4.2, 1.9; V2: 25.5, 0, 0; V3: 6.8, 0, 
0; V4: 18.8, 0, 0; V5: 29.5, 0, 0; V6: 47.9, 0, 0; V7: 50.0, 2.3, 1.9; V8: 42.0, 33.3, 12.3; V9: 44.7, 
26.7, 29.4 
Figure 3. Vitamin D metabolite (or PTH) concentration (mean and 95% confidence intervals), 
according to study visit (RECALL group only) 
A. Mean (SD) 25OHD in nmol/L from V0 to V9, respectively, was :  43.6 (21.1), 42.6 (21.8), 54.2 
(24.6), 65.2 (19.4), 56.0 (21.1), 48.2 (21.8), 43.6 (18.9), 40.4 (17.0), 43.2 (20.8), 41.5 (20.4) 
for placebo;  46.2 (19.2), 73.5 (16.5), 80.6 (17.0), 82.7 (18.5), 85.3 (18.2), 84.2 (18.2), 84.8 
(17.2), 72.5 (17.3), 49.2 (22.1), 45.5 (19.8)  for 400 IU vitamin D; and  43.7 (21.7), 73.2 (18.5), 
82.1 (18.8), 89.8 (20.9), 88.8 (20.3), 88.8 (23.3), 91.1 (24.3), 80.7 (17.0), 51.3 (17.4), 46.7 
(18.5) for 1000 IU vitamin D. 
B. Mean (SD) 24,25OHD in nmol/L from V0 to V9, respectively, was :  2.9 (1.9), 2.7 (1.7), 3.4 
(1.8), 4.7 (2.0), 4.2 (2.2), 3.3 (1.8), 2.8 (1.5), 2.6 (1.3), 3.2 (2.1), 3.0 (1.8) for placebo; 3.1 (1.5), 
5.0 (1.6), 6.1 (1.6), 6.4 (1.6), 6.6 (1.6), 6.3 (1.6), 6.4 (1.6), 5.8 (1.7), 3.7 (2.2), 3.2 (1.9)  for 400 
IU vitamin D; and 3.0 (2.0), 5.8 (1.9), 6.9 (2.1), 7.7 (2.4), 7.8 (2.4), 8.0 (2.9), 7.7 (2.7), 7.0 
(2.2), 4.4 (2.3), 3.5 (1.7)  for 1000 IU vitamin D. 
C. Mean (SD) 1,25OHD in pmol/L for V7, V8 and V9, respectively, was : 90 (37), 94 (33), 89 (36) 
for placebo; 104 (37), 100 (34), 93 (32)  for 400 IU vitamin D; and  95 (37), 93 (34), 99 (39) for 
1000 IU vitamin D 
D. Mean (SD) PTH for V0, V6, V8  and V9, respectively, was :  5.1 (1.2), 5.0 (1.1), 5.6 (1.7), 5.6 
(1.6) for placebo;  4.8 (1.5), 4.5 (1.2), 5.2 (2.1), 5.5 (2.0) for 400 IU vitamin D; and  5.2 (1.3), 
4.3 (1.0), 5.0 (1.3), 5.0 (1.3) for 1000 IU vitamin D 
Supplementary Figure 1. Daily UV exposure according to the month the badges were worn 
A. Median (IQR) for UVB exposure in SED each month from April 2012 to July 2013 (from April 
2012 to March 2013, average n=143; from April 2013-July 2013, average n=74): 0.2 (0.3), 0.7 
Figure legend Click here to download Figure figure legends footnotes.docx 
(0.8), 0.5 (0.4), 0.5 (0.6), 0.7 (0.7), 0.4 (0.5), 0.1 (0.2), 0.0 (0.1), 0.0 (0.0), 0.0 (0.0), 0.1 (0.1), 
0.1 (0.1), 0.4 (0.4), 0.7 (0.9), 0.7 (0.7), 1.1 (0.9). 
B. Median (IQR) for UVA exposure in SED each month from  August 2012 to July 2013 (average 
n 77) : 578 (945), 534 (1008), 152 (306), 56 (100), 18 (24), 24 (33), 45 (67), 105 (219), 227 
(566), 530 (993), 613 (862), 848 (1388). 
 
 
UVB 
 
UVA 
 
Supplementary figure Click here to download Supplementary MaterialSupplementary figure 1UVBUVA.docx
Supplementary Table 1. Differences in characteristics, measured at randomization for the VICtORY 
RCT (in 2009), between RECALL participants and those who did return for the RECALL visits (in 2012) 
* 25OHD measured by the tandem mass spectrometry but no de-lipidation of samples 
**1,25OH2D measured by immunoassay  
SED standard erythemal dose (100 J m-2) estimated from polysulphone badges 
 
Mean (SD) RECALL VICtORy non-returners p 
n 159 146  
Age (y) 64.7 (2.1) 64.5 (2.3) 0.499 
Height (cm) 161 (6) 161 (6) 0.425 
Weight (kg) 70.6 (11.1) 67.4 (12.8) 0.018 
Grip strength 22.3 (4.8)  22.5 (4.9) 0.784 
25OHD (nmol/L) * 34.3 (15.8) 33.4 (13.6) 0.915 
1,25OH2D (pmol/L)** 139 (46) 137 (41) 0.714 
n 158 137  
Dietary vitamin D (μg/d) 5.0 (2.7) 5.7 (4.8) 0.119 
Dietary calcium (mg) 1272 (528) 1285 (482) 0.822 
n 153 140  
Sunlight exposure  
baseline (SED/ week) 
0.85 (0.92) 0.89 (1.18) 0.761 
n 151 114  
Sunlight exposure  july-
august (SED/ week) 
6.15 (5.02) 7.13 (10.03) 0.302 
Supplementary Table Click here to download Supplementary MaterialSupplementary Tables.docx
Supplementary Table 2 Characteristics of between women below and above thresholds for (A) 25OHD (25 nmol/L) and (B) 24,25OH2D (2.2 nmol/L) at the 
final RECALL visit 
 (A) 25OHD:  25 nmol/L  (A) 24,25OHD: 2.2 nmol/L  
Mean (SD) Below threshold n=25 Above threshold n=120 P Below threshold n=48 Above threshold n=95 P 
Age (y) 65.0 (2.3) 64.5 (2.0) NS 64.8 (2.2) 64.5 (1.9) NS 
Weight (kg) 71.9 (18.4) 70.6 (10.7) NS 71.0  (12.8) 70.2 (10.5) NS 
VDBP (ug/ml) 250 (91) 269 (93) NS 265 (91) 266 (95) NS 
Energy intake (MJ/d) 9.18 (2.88) 8.97 (3.24) NS 9.44 (4.21) 8.81 (2.56) NS 
Dietary fat (g/d) 82.5 (34.4) 81.8 (32.3) NS 86.4 (40.5) 80.8 (29.8) NS 
Dietary protein (g/d) 92.3 (28.6) 92.1 (35.30 NS 95.0 (41.5) 90.9 (30.5) NS 
Dietary vitamin D 
(ug/d) 
5.5 (3.1) 5.1 (3.4) NS 5.57 (3.5) 5.0 (3.3) NS 
Dietary calcium 
(mg/d) 
1330 (608) 1247 (491) NS 1299 (665) 1243 (420) NS 
UVB June (SED) 17.4  17.3 NS 17.9 (14.8) 17.3 10.6) NS 
UVB July (SED) 23.0 20.4 NS  23.4 (19.5) 19.7 (14.5) NS 
UVB Aug (SED) 24.8 24.2 NS 24.2 (15.6) 24.2 (14.0) NS 
Holidays  win12-
spr13 
11 (17) 19 (21)  15 (19) 20 (22)  
25OHD start V0 33.9 (15.7) 45.5 (20.0) <0.01 35.4 (15.9) 47.9 (20.1) <0.01 
25OHD summer V3 72.2 (28.6) 82.1 (20.5) NS 75.5 (24.8) 82.8 (19.9) 0.07 
25OHD end V6 67.5 (38.1) 76.0 (27.1) NS 66.8 (33.5)  78.3 (25.4) 0.04 
Arm skin colour (ITA) 55.6  (6.1) 52.5 (5.4) 0.01 53.5 (5.8) 52.7 (5.4) NS 
1,25OH2D pmol/L  
V9 
77.3 (35.2) 96.2 (35.2) 0.02 82.3 (29.4) 99.1 (37.2) 0.08 
PTH pmol/L V9 5.5 (2.0) 5.3 (1.6) NS 5.7 (1.9) 5.2 (1.5) NS 
Categories        
% in placebo, 400 IU 
and 1000 IU 
44, 24, 32 31, 32, 37 NS 44, 25, 31 27, 35, 38 NS 
Supplement user % 12.0 25.0 NS 12.5 28.4 0.03 
Passive smoker 12.5 7.6 NS 6.4 9.5 NS 
 
 
  
